
==== Front
PLoS One
PLoS One
plos
PLOS ONE
1932-6203
Public Library of Science San Francisco, CA USA

10.1371/journal.pone.0309455
PONE-D-24-19541
Research Article
Biology and Life Sciences
Cell Biology
Cellular Types
Animal Cells
Bone Marrow Cells
Biology and Life Sciences
Cell Biology
Cellular Types
Animal Cells
Bone Marrow Cells
Erythroblasts
Biology and Life Sciences
Cell Biology
Cellular Types
Animal Cells
Blood Cells
Red Blood Cells
Erythroblasts
Biology and Life Sciences
Genetics
Gene Expression
Biology and Life Sciences
Physiology
Immune Physiology
Cytokines
Biology and Life Sciences
Immunology
Immune System
Innate Immune System
Cytokines
Medicine and Health Sciences
Immunology
Immune System
Innate Immune System
Cytokines
Biology and Life Sciences
Developmental Biology
Molecular Development
Cytokines
Biology and Life Sciences
Physiology
Immune Physiology
Spleen
Biology and Life Sciences
Cell Biology
Cell Motility
Chemotaxis
Chemokines
Biology and Life Sciences
Developmental Biology
Cell Differentiation
Biology and Life Sciences
Cell Biology
Cellular Types
Animal Cells
Bone Marrow Cells
Reticulocytes
Biology and Life Sciences
Cell Biology
Cellular Types
Animal Cells
Blood Cells
Red Blood Cells
Reticulocytes
Acute blood loss in mice forces differentiation of both CD45-positive and CD45-negative erythroid cells and leads to a decreased CCL3 chemokine production by bone marrow erythroid cells
Acute blood loss in mice forces differentiation of both CD45-positive and CD45-negative erythroid cells
Nazarov Kirill Investigation Validation Writing – original draft Writing – review & editing 1
https://orcid.org/0000-0002-5055-4859
Perik-Zavodskii Roman Conceptualization Formal analysis Software Visualization Writing – original draft Writing – review & editing 1 ‡
https://orcid.org/0000-0003-4911-1994
Perik-Zavodskaia Olga Formal analysis Software Visualization 1 ‡
https://orcid.org/0000-0003-0788-5385
Alrhmoun Saleh Formal analysis Software 1 ‡
Volynets Marina Formal analysis Software 1 ‡
Shevchenko Julia Data curation Methodology Supervision 1
https://orcid.org/0000-0002-7366-7768
Sennikov Sergey Conceptualization Project administration Supervision 1 2 *
1 Laboratory of molecular immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia
2 Department of Immunology, Zelman Institute for Medicine and Psychology, Novosibirsk State University, Novosibirsk, Russia
Stein Gary S. Editor
University of Vermont, UNITED STATES OF AMERICA
Competing Interests: The authors have declared that no competing interests exist.

‡ RPZ, OPZ, SA and MV also contributed equally to this work.

* E-mail: sennikov@nilkim.ru
4 9 2024
2024
19 9 e030945520 5 2024
9 8 2024
© 2024 Nazarov et al
2024
Nazarov et al
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Hemorrhage, a condition that accompanies most physical trauma cases, remains an important field of study, a field that has been extensively studied in the immunological context for myeloid and lymphoid cells, but not as much for erythroid cells. In this study, we studied the immunological response of murine erythroid cells to acute blood loss using flow cytometry, NanoString immune transcriptome profiling, and BioPlex cytokine secretome profiling. We observed that acute blood loss forces the differentiation of murine erythroid cells in both bone marrow and spleen and that there was an up-regulation of several immune response genes, in particular pathogen-associated molecular pattern sensing gene Clec5a in post-acute blood loss murine bone marrow erythroid cells. We believe that the up-regulation of the Clec5a gene in bone marrow erythroid cells could help bone marrow erythroid cells detect and eliminate pathogens with the help of reactive oxygen species and antimicrobial proteins calprotectin and cathelicidin, the genes of which (S100a8, S100a9, and Camp) dominate the expression in bone marrow erythroid cells of mice.

Ministry of Higher Education and Science 0415-2024-0012 https://orcid.org/0000-0002-7366-7768
Sennikov Sergey V. This research was funded by Ministry of Higher Education and Science, State Assignment No. 0415-2024-0012 awarded to SS. The specific roles of this author are articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data AvailabilityAll relevant data are within the manuscript and its Supporting Information files.
Data Availability

All relevant data are within the manuscript and its Supporting Information files.
==== Body
pmcIntroduction

Hematopoiesis in the body ensures the normal functioning of all organs and tissues without exception through the delivery of oxygen by red blood cells, removal of cellular debris and unnecessary substances, elimination of pathogens by immunocompetent cells, tissue remodeling by macrophages, neoangiogenesis, hemostasis, tolerance formation, immune memory, etc. We assume that the regulation of hematopoiesis and the immune response in the hematopoietic organs is carried out by humoral factors produced by erythroid precursor cells—erythroblasts. It has previously been shown that erythroblasts are capable of synthesizing cytokines [1], and the percentage of erythroblasts in hematopoietic organs, in particular in the bone marrow and spleen, is quite significant [2]. Moreover, the levels of cytokine production by erythroblasts are comparable to the levels of cytokine production by peripheral blood mononuclear cells, that is, lymphocytes, and monocytes [3].

In adults, the bone marrow is responsible almost exclusively for physiological erythropoiesis. However, in mice, about 10% of red blood cells are produced in the spleen. Stressful effects (trauma, hemolysis, etc.) activate mechanisms in the body for activating additional so-called foci of extramedullary erythropoiesis in the mouse, in particular in the spleen [2, 4]. In humans, extramedullary erythropoiesis is observed in patients suffering from hematological diseases and tumors. Activation of the glucocorticoid receptor GR is required for stress erythropoiesis and inhibition of differentiation in vitro. Interestingly, glucocorticoids activate essentially the same growth inhibition genes in erythroblasts and in lymphocytes, but growth inhibition is counteracted by EpoR/Kit activation, so glucocorticoids promote selective proliferation of erythroid progenitors, supporting erythroblast proliferation and suppressing the proliferation of other myeloid and lymphoid progenitor cells [5]. Fas and FasL are important regulators of immune response and hematopoiesis. Although Fas is expressed on human erythroblasts at all stages of terminal differentiation, only immature erythroblasts die apoptosis by Fas-way. FasL is not expressed until late stage differentiation and orthochromatic erythroblasts exhibit Fas-based cytotoxicity toward immature erythroblasts. However, erythropoietin receptor signaling downregulates erythroblast Fas and FasL during stress thereby preserving the erythropoietic response to stress [6, 7]. Interestingly, Fas overexpression has been detected in CD34+ stem cells from aplastic anemia patients, which may contribute to the suppression of hematopoiesis in this severe disease [8]. Also, it has been shown that erythroferrone protein is the main erythroid regulator of hepcidin, the homeostatic hormone controlling plasma iron levels and total body iron. After stimulation, differentiating erythroblasts in the bone marrow and spleen rapidly increase ERFE production in an EPO-Stat5 dependent manner. ERFE is secreted into the circulation and acts directly on the liver to repress hepcidin. ERFE-mediated hepcidin suppression in turn increases iron availability for new red blood cells synthesis [9, 10]. Acute blood loss (ABL), accompanied by most injuries, represents a request to the hematopoietic organs for new blood cells of all cell types. Post-acute blood loss myeloid and lymphoid cells have been studied in detail, but the immunological changes in the erythroid cells during blood loss have been studied less widely, which, in fact, is what our study was aimed at—to expand the understanding of the role of erythroid cells and to decipher their immune mechanisms of action in the post-acute blood loss period.

Materials and methods

Mice

We obtained male mice ♂F1 CBA×C57Bl6 3–5 months old from the vivarium of the Institute of Cytology and Genetics and used them in all experiments. Mice lived in conventional vivarium conditions with water and food access ad libitum, under the natural dark/light cycle. All experiments using mice were approved by the local ethics committee of RIFCI.

Murine acute blood loss model

Acute blood loss was performed as follows: In mice under isoflurane anesthesia (Aerran, Baxter), ~0.5–0.8 ml of blood was collected from the retro-orbital sinus using a glass capillary with a pointed tip. The onset of surgical anesthesia and recovery from anesthesia for each animal were monitored. Bone marrow and spleens were collected on the third day after the start of the experiment. Similar intact animals were used as control (conditional norm).

Mononuclear cell isolation

We harvested femurs (normal bone marrow − n = 4, post-ABL bone marrow − n = 4) and spleens (normal spleen − n = 4, post-ABL spleen − n = 4) from mice aseptically. We obtained bone marrow cells by washing the bone marrow canal using PBS. We obtained splenocytes by homogenizing the whole spleen in a glass homogenizer. We centrifuged splenocytes in density gradient Ficoll-Urografin (ro = 1,119 g\cm^3) for 30 min at 322 RCF and washed them twice in PBS to delete RBC and granulocytes.

Flow cytometry

We washed 0,5*10^6 cells in PBS with the addition of 0,09% NaN3 and stained them with the antibodies according to the manufacturer’s protocols. We used Pacific Blue™ anti-mouse TER-119/erythroid Cells Ab #116207, PE anti-mouse/human CD44 Ab #103024, FITC anti-mouse CD45 Ab #304006, and APC anti-mouse CD71 Ab #113820 (Biolegend, San Diego, California, United States). We then washed the cells after 30 minutes of incubation in the dark with 0,5 ml PBS with the addition of 0,09% NaN3. We added 7AAD to all samples right before cytometry. We conducted flow cytometry on the Attune NxT flow cytometer (Thermo Fisher Scientific, Waltham, Massachusetts, United States). We manually gated Ter-119+ cells as follows: we gated cells from all events, gated singlets from the cells, gated alive cells from the singlets, and gated Ter-119+ erythroid cells (Scheme 1) in conventional gating software (for Attune NxT) and exported them as.fcs files.

Flow cytometry data analysis

Ter-119+ erythroid cell.fcs files were then transformed into.csv files using fcsparser library for Python 3. Csv files containing flow cytometry data were arcsinh-transformed, fdaNorm-normalized and exported as.fcs files with the R script published by Melsen et al [11]. We identified erythroid cell clusters i.e. stages of erythroid differentiation using the prior knowledge that CD71 expression is the highest at the proerythroblast stage and then continuously decreases until it disappears at the reticulocyte stage, Ter-119 is present on all mouse Ter-119+ erythroid cells. We then exported cluster cell count data into GraphPad Prism 10.2.3. We used either one-way ANOVA with Tukey correction for multiple testing (for the analysis of Ter-119+ erythroid cells in bulk) or two-way ANOVA with Tukey correction for multiple testing for our statistical analyses (for percentage analysis of differentiation stages of Ter-119+ erythroid cells).

Magnetic separation

We performed magnetic separation of mononuclear splenic cells and marrow cells using anti-Ter-119-biotinylated antibodies (#113803, Biolegend, San Diego, California, United States) and streptavidin-linked magnetic beads (#480015, Biolegend, Biolegend, San Diego, California, United States) according to the manufacturer’s protocols (MojoSort™ Streptavidin Nanobeads Column Protocol – Positive Selection, accessed on 13.04.2024) to obtain Ter-119+ erythroid cells.

Cell viability staining

We measured Ter-119+ erythroid Cells’ viability on a Countess 3 Automated Cell Counter (Thermo Fisher Scientific, Waltham, Massachusetts, United States) according to the manufacturer’s protocols using Trypan Blue. Trypan Blue staining showed > 95% viability for the magnetically separated Ter-119+ erythroid cells.

Total RNA extraction

We isolated total RNA from 500,000 Ter-119+ erythroid cells with the Total RNA Purification Plus Kit (Norgen Biotek, Thorold, ON, Canada). We measured the concentration and quality of the total RNA in each sample on a Qubit 4 (Thermo Fisher Scientific, USA). We froze the total RNA at −80°C until the gene expression analysis.

Gene expression profiling

We performed gene expression profiling using the NanoString nCounter SPRINT Profiler analytical system using 100 ng of total RNA from each Ter-119+ erythroid cell sample. We used the nCounter Mouse Immunology v1 panel (561 immunity-related genes, 15 housekeeping genes, 6 positive and 8 negative controls) to analyze the total RNA samples. The samples (normal bone marrow − n = 3, post-ABL bone marrow − n = 3) were subjected to a 20 h hybridization reaction at 65°C, where 5–14 μL of total RNA was combined with 3 μL of nCounter Reporter probes, 0–9 μL of DEPC-treated water, 12 μL of hybridization buffer and with 5 μL of nCounter capture probes (total reaction volume = 36 μL).

After the hybridization of the probes to targets of interest in the samples, the counts of target molecules were determined on the nCounter digital analyzer. We performed normalization and QC in nSolver 4 using added synthetic positive controls and the Gapdh, Rpl19, Ppia, Oaz1, Eef1g, Polr2a, G6pdx, Gusb, Sdha, and Alas1 housekeeping genes included in the panel. We then performed background thresholding on the normalized data to remove non-expressing genes. We determined the background level as the mean of the POS_E controls and removed the genes that were below the background level in all samples.

We log2-transformed the gene expression counts data. We then performed differential gene expression analysis using multiple t-tests (we considered Fold Change > 2 or Fold Change < −2 and q-values < 0.01 statistically significant) and created a Volcano plot in GraphPad Prism 10.2.3. We created a heat map of the up-regulated and key erythroid cell genes via Bioinfokit [12] and performed Gene Ontology Biological Process overrepresentation analysis of the up-regulated differentially expressed genes via GSEApy [13].

Cell culturing

We cultured the magnetically sorted cells in the X-VIVO 10 serum-free medium with the addition of x1 Insulin-Transferrin for 24 h at a concentration of 1 million per mL of the medium in order to support their viability and measure culture media cytokines afterward.

Conditioned media harvesting

We separated Ter-119+ erythroid cell conditioned media from cells after 24 h of culturing. We did the separation by centrifugation at 1500 rpm for 10 minutes, transferred the Ter-119+ erythroid cell conditioned media into new 1,5 mL tubes with the addition of BSA up to the total concentration of 0,5%, and froze the cells’ conditioned media at −80°C until the cytokine quantification.

Cytokine quantification in culture medium using BioPlex

We prepared 50 μL of each Ter-119+ erythroid cell conditioned media sample (n = 4 for each bio-group) for a cytokine quantification with a Bio-Plex Pro mouse cytokine 23-Plex assay (#M60009RDPD, BioRad, Hercules, California, United States) according to the manufacturer’s recommendations and analyzed them on the Bio-Plex 200 instrument.

We log2-transformed the Bio-Plex cytokine data using Pandas and then performed multiple T-tests with FDR correction for differential cytokine production analyses (we considered Fold Change > 4 or Fold Change < −4 and q-values < 0.05 statistically significant) and created the Volcano plots in GraphPad Prism 10.2.3. We created the heatmap of the profiled cytokine concentrations via Bioinfokit [12].

Results

Acute blood loss leads to a decrease in the absolute number of Ter-119+ erythroid cells in the hematopoietic organs of mice

In this work, we analyzed the content of mouse Ter-119+ erythroid cells in the bone marrow and spleen under normal conditions and after acute blood loss. The analysis showed that the content of Ter-119+ erythroid cells in the mouse bone marrow after blood loss is significantly reduced in comparison with intact animals. Also, during blood loss, the content of Ter-119+ erythroid cells in the spleen is significantly lower in comparison with intact animals (Fig 1).

10.1371/journal.pone.0309455.g001 Fig 1 Percentages of Ter-119+ erythroid cells in the bone marrow and in the spleen in normal condition and after ABL, **** depict statistically significant differences (q-values < 0.00005).

Acute blood loss leads to stimulation of terminal differentiation of both CD45-negative and CD45-positive Ter-119+ erythroid cells

Then, by applying HSNE (Hierarchic Stochastic Neighbor-Embedded) dimensionality reduction to Arcsinh-transformed and fdaNorm-normalized flow cytometry parameters (FSC, SSC, CD44, CD45, CD71 and Ter-119) of the Ter-119+ erythroid cells, we found clusters corresponding to successive stages of differentiation of Ter-119+ erythroid cells in both branches of murine erythropoiesis–CD45− and CD45+ (Fig 2).

10.1371/journal.pone.0309455.g002 Fig 2 Integrated HSNE plots of erythroid cells from the bone marrow and the spleen.

Integrated HSNE plots of erythroid cells from the bone marrow and the spleen overlaid with marker expression (see Fig 1 for gating)—the purple color represents the absence of the marker expression whereas the yellow color represents the maximum of the marker expression. Clusters are color-labeled in accordance with the heatmap. The heatmap shows mean hyperbolic arcsine-transformed marker expression values. The yellow color represents the highest standardized expression, and the purple color represents the lowest standardized expression. Pro stands for proerythroblasts, Baso stands for basophilic erythroblasts, Poly stands for polychromatophilic erythroblasts, Ortho stands for orthochromatophilic erythroblasts, and Retic stands for reticulocytes.

Stage-by-stage analysis of Ter-119+ erythroid cells showed the presence of statistically significant changes in the structure of erythron. We found that ABL leads to: 1) a significant increase in the relative number of CD45+ proerythroblasts, CD45+ basophilic erythroblasts, CD45+ polychromatic erythroblasts and CD45− basophilic erythroblasts in the bone marrow, 2) a significant decrease in the relative number of CD45+ and CD45− reticulocytes, CD45− polychromatic and CD45− orthochromatic erythroblasts in the bone marrow, 3) a significant increase in the relative number of CD45+ proerythroblasts, CD45+ basophilic erythroblasts, CD45+ polychromatic erythroblasts and CD45− basophilic erythroblasts in the spleen, 4) a significant decrease in the relative number of CD45+ orthochromatic erythroblasts, CD45+ reticulocytes, CD45− polychromatic and orthochromatic erythroblasts and CD45− reticulocytes in the spleen (Fig 3).

10.1371/journal.pone.0309455.g003 Fig 3 Percentages of Ter-119+ erythroid cells at the sequential stages of differentiation in the bone marrow and in the spleen in normal condition and after the ABL, **, ***, **** depict statistically significant differences (q-values < 0.005, q-values < 0.0005, and q-values < 0.00005 respectively).

Acute blood loss leads to the down-regulation of the MHC Class II antigen presentation genes in Ter-119+ erythroid cells

Then we analyzed the expressed genes by the Ter-119+ erythroid cells from the bone marrow cells after the acute blood loss and in normal conditions using the NanoString method on the Sprint platform using the Mouse Immunology V1 panel. The studied Ter-119+ erythroid cells expressed the signature genes of erythroid cells Tfrc, Tal1, and Cd36 in a large number of copies, which shows the high purity of the magnetically-sorted cells. Among the genes expressed by Ter-119+ erythroid cells, expression of the cytokine and chemokine genes (in order of decreasing copy number): Ccl3, Tgfb1, Il1b, Cxcl12, Ccl2, Mif, and Il16, as well as the antimicrobial response genes S100a9, S100a8, and Camp was detected (Fig 4A and 4B).

10.1371/journal.pone.0309455.g004 Fig 4 Differential gene expression analysis of the post-ABL erythroid cells.

(A) Volcano plot of post-ABL Ter-119+ erythroid cells from the bone marrow (Eb BM ABL) versus normal Ter-119+ erythroid cells from the bone marrow (Eb BM N); (B) heat map of the up-regulated and key erythroid cell genes.

We found statistically and biologically significant changes in gene expression (Fig 4A). We found that after the acute blood loss, Ter-119+ erythroid cells from the bone marrow had higher expression of the genes: Csf3r, Cdkn1a, Ctsg, Hlx, Clec5a, and Ltb4r1; and significantly lower expression of the genes: Cxcl12, Il1r2, Ccr2, Psmc2, Tnfaip3, Cd2, Cd79b, Cd55, Cd24a, C1qbp, Pml, Ms4a1, Itga4, Itgb1, Ptpn2, Ctnnb1, Irgm1, H2-Aa, and H2-Ab1 (Fig 4A, Table 1).

10.1371/journal.pone.0309455.t001 Table 1 Differential gene expression analysis of the post-ABL erythroid cells.

We considered q-values < 0.01 and log2(FC) < -1 or log2(FC) > 1 significant.

Genes	log2(FC)	q-value	log2(Mean)	
Hlx	1,87477	0,003304	7,00494703	
Ltb4r1	1,519352	0,000657	7,28639282	
Ctsg	1,302794	0,003344	10,0653283	
Csf3r	1,274738	0,001566	7,83427247	
Clec5a	1,249117	0,003317	8,61593601	
Cdkn1a	1,169783	0,001747	7,79369334	
Clec4e	1,047907	0,016741	9,53992569	
Nfil3	0,896776	0,012434	7,37469849	
Nfkbia	0,834517	0,000424	8,94117584	
Camp	0,768596	0,004611	14,457602	
Cebpb	0,760538	0,001692	9,69110485	
Vcam1	0,757209	0,039872	7,56620367	
Ifngr1	0,720312	0,003164	9,087193	
Itgb2	0,717999	0,00451	8,31901438	
S100a8	0,654607	0,016343	17,0360661	
Sell	0,631787	0,021061	9,03527089	
Ptafr	0,586265	0,001359	7,9906437	
Mapkapk2	0,563661	0,014714	8,34572552	
Cxcr4	0,552018	0,010638	10,4247994	
Ifnar2	0,490648	0,014312	8,25010048	
Plaur	0,422957	0,05239	10,2709953	
Cd97	0,378523	0,002191	8,22042178	
Irf1	0,359004	0,05239	7,98611696	
Cfp	0,322791	0,11648	8,35442409	
App	0,310457	0,007493	8,31720621	
Itgam	0,292408	0,049542	9,0953678	
Cybb	0,2923	0,05239	11,2064301	
Litaf	0,267387	0,031155	8,87761634	
Cd83	0,243612	0,049542	8,5578499	
C3	0,225728	0,086791	9,51335317	
Arhgdib	0,216435	0,049542	12,0132289	
H2-Ea-ps	0,196731	0,137257	9,43008862	
Cd44	0,194485	0,033312	9,67751557	
Fcgr2b	0,188873	0,179545	9,18894842	
Stat3	0,179201	0,100932	8,52522078	
Ncf4	0,165842	0,06747	10,2195464	
Tyrobp	0,149933	0,224617	11,7889501	
Ptprc	0,10363	0,204569	9,37343616	
Fcgr3	0,077704	0,182963	7,99295713	
Xbp1	0,044349	0,302128	9,67757626	
Ebi3	0,043823	0,354737	8,04141273	
Ptpn6	-0,007568	0,437307	8,92708144	
Mif	-0,019966	0,415805	8,41776078	
Il16	-0,048724	0,37735	8,33101138	
Tgfbi	-0,070686	0,364214	8,4088589	
Trem1	-0,070816	0,30342	9,27818248	
Fcer1g	-0,086386	0,274702	9,05310621	
Ifnar1	-0,097318	0,203519	8,56088964	
S100a9	-0,100654	0,32006	17,6473253	
Nfkbiz	-0,117015	0,324631	9,50509942	
Cd74	-0,119386	0,281878	11,0092219	
Cd9	-0,139032	0,193707	8,68109707	
Spn	-0,14196	0,100932	8,41126195	
H2-K1	-0,215382	0,177752	9,03037983	
Jak2	-0,229355	0,120807	8,56593721	
Il1b	-0,231095	0,071378	9,32521239	
Abcb10	-0,237792	0,182963	9,33599829	
Prkcd	-0,26005	0,0814	8,61452084	
Ctss	-0,276268	0,198094	9,08573067	
Jak1	-0,301748	0,000314	9,41180728	
Lilrb4	-0,30381	0,140438	10,6373557	
Cd164	-0,349859	0,001692	9,94146245	
Nfkb2	-0,359722	0,013041	8,04800464	
Il17ra	-0,375208	0,05812	8,39730795	
Tgfb1	-0,388059	0,010638	9,46170607	
Cd82	-0,4315	0,049542	9,99165444	
Bcap31	-0,435809	0,000657	8,68275083	
Ccl9	-0,457302	0,054017	9,16465069	
Psmd7	-0,471534	0,009418	8,88312017	
Stat6	-0,490435	0,005473	7,95969364	
Syk	-0,513637	0,00598	9,49659107	
Ppbp	-0,513691	0,30342	6,66284178	
C1qa	-0,519964	0,148378	7,83628645	
Tnfrsf14	-0,536492	0,087313	10,2727077	
Cd81	-0,563596	0,003304	9,42096958	
Mapk1	-0,572596	0,003317	9,51826507	
Fn1	-0,576091	0,058418	8,34606556	
B2m	-0,578546	0,002599	12,4807427	
Casp3	-0,581552	0,019845	8,91919995	
Tollip	-0,582838	0,002986	9,1485353	
Icam4	-0,584225	0,052683	9,16782842	
Ccrl2	-0,632056	0,001527	8,71454491	
Ube2l3	-0,663464	0,003317	8,5241204	
Tfrc	-0,723355	0,044203	12,9232084	
Tal1	-0,742908	0,046603	10,4227882	
Mapk14	-0,759993	0,002191	8,52707519	
Psmb7	-0,832746	0,000424	9,62649923	
Rela	-0,843845	0,001286	8,05856486	
Ets1	-0,858636	0,003317	8,93834805	
Prim1	-0,862025	0,004396	9,01273565	
Ccl2	-0,912534	0,055319	8,04693254	
H2-Eb1	-0,927035	0,007	7,9830276	
Ccl3	-0,934065	0,012244	9,29790947	
Rae1	-0,961163	0,002987	8,80530261	
Chuk	-0,967619	0,004611	7,63159427	
Psmb5	-0,973113	0,000314	8,64915252	
Cd24a	-1,024528	0,004396	14,1815281	
H2-Aa	-1,044709	0,003916	10,5056178	
C1qbp	-1,100559	0,003916	9,17332236	
Psmc2	-1,128281	0,000314	10,3143583	
Irgm1	-1,147005	0,000424	8,04646398	
Tnfaip3	-1,331172	0,000424	9,6579562	
Cd36	-1,363871	0,016741	9,89639128	
Itgb1	-1,380271	0,000482	9,68691756	
Ms4a1	-1,380661	0,002599	7,54883028	
Ptpn2	-1,394648	0,000432	7,71107503	
Ctnnb1	-1,44872	0,000424	9,49272111	
Cd55	-1,455002	0,003317	8,11573244	
Pml	-1,536634	0,003304	8,35742732	
C1qb	-1,55099	0,02576	8,1762979	
Ccr2	-1,564424	0,000424	8,25134501	
Cd79b	-1,581816	0,001692	8,14782409	
Itga4	-1,703999	0,002539	8,82683222	
Il1r2	-2,073272	0,000314	10,0327108	
Cd2	-2,363551	0,000424	8,05803935	
Cxcl12	-3,8068	0,000583	7,40617888	
H2-Ab1	-4,877545	0,000413	6,94301249	

We also decided to analyze the biological processes occurring in Ter-119+ erythroid cells after the acute blood loss by analyzing invariant (non-up- or down-regulated genes) and up-regulated genes using Gene Ontology Biological Process (GO BP) Overrepresentation Analysis and found enrichment in GO BP terms associated with reactive oxygen species synthesis and myeloid cell activation (Fig 5, Table 2).

10.1371/journal.pone.0309455.g005 Fig 5 Gene Ontology Biological Process overrepresentation analysis of the genes expressed in the post-ABL Ter-119+ erythroid cells, the yellow color corresponds to the lowest q-value, the deep purple color corresponds to the highest q-value, and the dot size reflects the percentage of genes included in the analysis relative to the full set of genes in the Gene Ontology Biological Process database.

10.1371/journal.pone.0309455.t002 Table 2 Gene Ontology Biological Process overrepresentation analysis of the genes expressed in the post-ABL Ter-119+ erythroid cells.

Term	Overlap	Q-value	Score	Genes	
Positive Regulation Of Superoxide Anion Generation (GO:0032930)	6/13	0.00000	4694	ITGAM, TGFB1, TYROBP, SYK, ITGB2, PRKCD	
Regulation Of Superoxide Anion Generation (GO:0032928)	6/14	0.00000	4015	ITGAM, TGFB1, TYROBP, SYK, ITGB2, PRKCD	
Positive Regulation Of Reactive Oxygen Species Metabolic Process (GO:2000379)	8/48	0.00000	1057	CDKN1A, ITGAM, TGFB1, TYROBP, SYK, ITGB2, PRKCD, MAPK14	
Neutrophil Activation (GO:0042119)	6/18	0.00000	2477	FCER1G, TYROBP, SYK, PRKCD, CTSG, CAMP	
Macrophage Activation (GO:0042116)	7/35	0.00000	1227	APP, C1QA, ITGAM, SYK, IFNGR1, ITGB2, JAK2	
Leukocyte Aggregation (GO:0070486)	4/7	0.00000	5156	IL1B, S100A9, CD44, S100A8	
Regulation Of Alpha-Beta T Cell Proliferation (GO:0046640)	4/7	0.00000	5156	SYK, IRF1, EBI3, TNFRSF14	
Cellular Response To Low-Density Lipoprotein Particle Stimulus (GO:0071404)	5/22	0.00000	1073	FCER1G, SYK, CD81, ITGB2, CD9	
Type II Interferon-Mediated Signaling Pathway (GO:0060333)	4/9	0.00000	2873	IFNGR1, IRF1, JAK2, JAK1	
Astrocyte Development (GO:0014002)	4/15	0.00000	1120	APP, C1QA, IFNGR1, S100A9	

Analysis of the down-regulated genes revealed that normal bone marrow murine erythroid cells had significantly higher gene expression of the genes that belong to the MHC Class II antigen presentation GO BP Biological Process compared with post-ABL erythroid cells.

Ter-119+ erythroid cells secrete the chemokines CCL2, CCL3 and the cytokine IL1b

We also studied the cytokine secretion of Ter-119+ erythroid cells in the bone marrow and spleen in normal conditions and after acute blood loss. The largest amounts of detected secreted cytokines were the chemokines CCL2 and CCL3. We also detected some production of the cytokine IL-1b. The list of detected cytokines is in accord with the NanoString gene expression analysis–we detected Ccl2, Ccl3 and Il1b gene expression and have not detected gene expression of the undetected cytokines by the Bio-Plex method (see Fig 4A). Moreover, the production of the chemokine CCL3 by Ter-119+ erythroid cells from the bone marrow was significantly lower after the acute blood loss compared to the normal bone marrow Ter-119+ erythroid cell CCL3 levels (Fig 6).

10.1371/journal.pone.0309455.g006 Fig 6 Cytokine production profiles of the Ter-119+ erythroid cell.

(A) heat map of the cytokines secreted by Ter-119+ erythroid cells. Eb stands for Ter-119+ erythroid cells, Bm stands for Bone Marrow, Spl stands for Spleen, N stands for normal, ABL stands for post-acute blood loss; (B) Volcano-plot of the differentially secreted cytokines by Ter-119+ erythroid cells from the bone marrow; (C) Volcano-plot of the differentially secreted cytokines by Ter-119+ erythroid cells from the spleen.

Discussion

Our data allow us to say that acute blood loss has a powerful disturbing effect on hematopoiesis, especially erythropoiesis. With acute blood loss, blood leaks out of the body, therefore there is hypovolemia and loss of all blood cells without exception.

We noticed that during blood loss in mice, the content of erythroblasts decreases in the bone marrow and in the spleen, which is probably due to the acceleration of erythroblast maturation and the release of reticulocytes into the peripheral blood. Several arguments can be given in favor of this thesis by analyzing changes in the phenotypic forms of erythron in hematopoietic organs. As we noticed, the bone marrow and spleen react to acute blood loss in a similar way—by accelerating the maturation of the CD45– and CD45+ branches of Ter-119+erythroid cells. It can be seen that in both the bone marrow and the spleen, during blood loss, the content of early maturation forms–proerythroblasts, basophilic erythroblasts—- significantly increases, and the content of late maturation forms—orthochromatophilic erythroblasts and reticulocytes drops drastically; apparently, reticulocytes do not remain in the hematopoietic organs for long, but are released into the peripheral blood as soon as possible.

Also, with blood loss in the bone marrow and spleen, the proportion of early forms—proerythroblasts, basophilic erythroblasts—increases, indicating accelerated proliferation and maturation of erythroid cells. However, the following difference can be noted: CD45+ and CD45- branches respond to acute blood loss differently, in particular different potency of CD45+ and CD45- polychromatic erythroblasts to division and maturation. We observed increased content of marrow CD45+ polychromatic erythroblasts after acute blood loss. Also, we noticed an increased content of splenic CD45+ polychromatic erythroblasts after acute blood loss. However, the content of CD45- polychromatic erythroblasts decreased in the marrow and in the spleen after acute blood loss. Hence, we have hypothesized that CD45+ polychromatic erythroblasts have the tendency to have more division and differentiation than CD45- polychromatic erythroblasts which behave like reticulocytes because CD45- polychromatic erythroblasts release to the bloodstream like reticulocytes and finish the maturation in the blood. We suppose the decreasing CD45- polychromatic erythroblasts content in the hematopoietic organs connects with their exit to the bloodstream. But these suggestions need to be proofed. We can say that in conditions of blood loss when the body has a request for new blood cells, in particular, red blood cells, erythron responds with accelerated maturation of CD45– Ter-119+ erythroid cells to replenish lost red blood cells. Something similar was described by Shahbaz and co-authors [14]. With COVID-19, an increase in immature erythroid cells occurs in the human bone marrow, and erythroblasts are also found in the peripheral blood, and this phenomenon correlates with the severity of the infection. That is, under conditions of increasing tissue hypoxia with lung damage, when the body has a request for new red blood cells, increased proliferation of the erythroid sprout occurs, and even the release of nuclear erythroid cells into the bloodstream as a compensatory effect.

Gene expression analysis allowed us to delineate the list of cytokines expressed in Ter-119+ erythroid cells: Ccl3, Tgfb1, Il1b, Cxcl12, Ccl2, Mif, and Il16. These cytokines are represented by chemokines, proinflammatory IL1B, and tolerogenic TGFB1, which suggests different and multidirectional immunoregulatory functions for Ter-119+ erythroid cells—chemoattraction, immunosuppression, and initiation of inflammation (Fig 4B). We also previously demonstrated the expression of chemokine genes in human erythroid cells [15, 16]. Gene Ontology Biological Process analysis for genes active in Ter-119+ erythroid cells of the bone marrow after acute blood loss showed the presence of an active process of synthesis of reactive oxygen species in erythroid cells, which is consistent with literature data [17].

With blood loss in Ter-119+erythroid cells of the bone marrow, the expression of some genes increases, such as Csf3r, Cdkn1a, Ctsg, Hlx, Clec5a, and Ltb4r1. The Clec5a gene encodes the CLEC5A protein, which is a pathogen-associated molecular pattern (PAMP) recognition receptor [18], which may indicate the involvement of Ter-119+ erythroid cells in the process of innate immunity through sensing of PAMPs using CLEC5A and elimination of detected pathogens by the proteins Calprotectin (S100a8 and S100a9 genes) and Cathelicidin (Camp gene) [19] expressed by Ter-119+ erythroid cells (Fig 4B).

The Csf3r gene product is a G-CSF receptor expressed primarily by hematopoietic stem cells and myeloid lineage cells. This receptor is necessary for the rapid release of cells into the bloodstream during the mobilization of hematopoiesis [20]. Perhaps its increased expression in erythroblasts during blood loss is necessary to accelerate the maturation and further release of erythroid cells into the bloodstream.

The Cdkn1a (p21) gene encodes a protein inhibitor of cyclin-dependent kinase 1a, thereby preventing the cell from entering the G1 phase of the cell cycle, and maintaining the cell in the resting phase. During blood loss in bone marrow erythroblasts, we noticed a significant increase in the expression of the Cdkn1a gene, however, it must be said that the cell cycle of an erythroblast is very different from other cells, since erythropoiesis is a unique process in which each cell division is simultaneously associated with the stage of differentiation [21]. Elevated levels of Cdkn1a mediate erythroblast apoptosis in beta-thalassemia but do not improve erythropoiesis [22].

We also showed that during acute blood loss in erythroblasts, the expression of Mif does not change significantly. It is known that this cytokine interacts with its receptor CD74, the gamma chain of MHC class II, therefore their interaction is important for antigen presentation. It was shown that erythroblasts in all cases we studied express Cd74. Moreover, under any influences, as well as during ontogenesis, the expression of Cd74in erythroid cells does not change. It has also been shown that blockade or deletion of CD74 leads to the accumulation of hematopoietic stem cells in the bone marrow [23].

We also detected the expression of genes associated with the presentation of exogenous antigen in the MHC class II complex in the normal bone marrow murine Ter-119+ erythroid cells: Ctsg, Cd74, H2-Aa, and H2-Ab1, which suggests the possibility of presentation of exogenous antigen by mouse bone marrow erythroid cells. The presence of expression of exogenous antigen presentation genes in the MHC class II complex, coupled with the production of reactive oxygen species and their expression of antimicrobial genes S100a8, S100a9, and Camp, makes the transcriptome of Ter-119+ erythroid cells functionally similar to that of classical monocytes [24, 25]. The expression of the H2-Aa and H2-Ab1 genes was down-regulated after acute blood loss, which suggests a disruption in the process of exogenous antigen presentation, provided that such a process is actually present in Ter-119+ erythroid cells.

The list of cytokines detected by the Bio-Plex method was in accord with the NanoString gene expression analysis–we have found both gene expression and cytokine secretion of CCL2, CCL3, and IL-1b. The production of chemokines and cytokines by Ter-119+ erythroid cells undergo slight changes after the acute blood loss: bone marrow erythroblasts produce significantly less chemokine CCL3 compared to normal. The decreased CCL3 chemokine production may lead to a reduced chemoattraction of cells that express CCR1, CCR4, and CCR5 chemokine receptors. Some authors suggest the prognostic role of CCL3 in autoimmune diseases such as multiple sclerosis [26]. In light of erythropoiesis, elevated levels of CCL3 in the serum of patients with multiple myeloma have been described to suppress the maturation of erythroblasts into reticulocytes, leading to anemia [27]. It can be assumed that CCL3 has an indirect effect on erythropoiesis and, in our case, post-acute blood loss, its reduced production can be explained by the need for new red blood cells in the body and the acceleration of maturation of erythroid progenitor cells. Previously, in our secretomic analysis of the healthy adult human erythroid cell conditional media we have found the secretion of CCL22, CCL24, CXCL5, CXCL8, and MIF chemokines. This spectrum of chemokines could allow erythroid cells to attract neutrophils and eosinophils, which could help erythroid cells restrict the aforementioned cell types to the bone marrow in normal condition or initiate their migration to a site of extramedullary erythropoiesis. Maybe it makes chemokine secretion feature evolutionary conservative among erythroid cells [28].

Conclusions

Acute blood loss stimulates terminal differentiation of erythroid cells in the murine bone marrow and spleen, with a decrease in the relative number of erythroid cells in the bone marrow, and also leads to the up-regulation of several immunity-related genes, including the pathogen sensor gene Clec5a in bone marrow erythroid cells, which could help bone marrow erythroid cells detect pathogens and eliminate them with the help of reactive oxygen species and antimicrobial proteins calprotectin and cathelicidin, the genes of which (S100a8, S100a9, and Camp) dominate in expression in bone marrow erythroid cells of mice.

Supporting information

S1 Graphical abstract (TIF)

Graphical Abstract was created using BioRender.

10.1371/journal.pone.0309455.r001
Decision Letter 0
Stein Gary S. Academic Editor
© 2024 Gary S. Stein
2024
Gary S. Stein
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version0
26 Jun 2024

PONE-D-24-19541Acute blood loss in mice forces terminal differentiation of the CD45-negative erythroid cells and up-regulation of the pathogen-sensing gene Clec5a in bone marrow erythroid cellsPLOS ONE

Dear Dr. Sennikov,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 10 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Gary S. Stein

Academic Editor

PLOS ONE

Journal requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service. 

The American Journal Experts (AJE) (https://www.aje.com/) is one such service that has extensive experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. Please note that having the manuscript copyedited by AJE or any other editing services does not guarantee selection for peer review or acceptance for publication. 

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

https://www.sciencedirect.com/science/article/pii/S0163725821001297?via%3Dihub

https://www.mdpi.com/1422-0067/24/9/8130

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

4. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and its Supporting Information files.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this manuscript, Nazarov et al. aimed at investigating the immune function of the erythrocytes induced by acute blood loss (ABL). To this end, the authors collected the bone marrow and spleens of mice three days after blood drawn, and performed flow cytometry analysis of the different stages of erythrocytes, Nanostring gene expression profiling of immune response genes, and BioPlex analysis of multiple cytokines in the media conditioned with cultured erythrocytes. While the potential immune function of the erythrocytes upon ABL is interesting, this manuscript, at least in its current form, seems to be too preliminary and does not achieve its aim very well, because it lacks sufficient information for describing the background, rationale for experimental design, and inter-validation of the different parts of the results. Specific concerns include:

1. The notion that erythrocyte differentiation can be stimulated by ABL has been well documented (e.g., reviewed by Valent et al. Haematologica. 2018, 103(10):1593-1603; Srole and Ganz. J Cell Physiol. 2021, 236(7):4888-4901). Although the current study might provide more details, the authors should cite the previous studies and make necessary comparisons. Any new finding or discrepancy (e.g., the decrease of reticulocytes upon ABL, as shown in Fig. 3) should be described and explained in detail.

2. In Figs. 1 and 3, besides the statistical analysis results, representative results of flow cytometry analysis of the bone marrow and spleen samples upon ABL should also be provided for readers’ better understanding and for objective evaluation of the quality of the data.

3. In the “Acute blood loss leads to the up-regulation of the pathogen-sensing Clec5a gene and the down-regulation of the early erythroid cell genes Itga4 and Itgb1 in Ter-119+ erythroid cells” section, too many gene names were simply listed in the main text. It would be better to put them in a table, together with the values of their expression levels in different samples.

4. Clec5a seems to be just one of the many differentially expressed genes. Without more technical validation, determination of its protein level, or functional experiments to explain its role in the erythrocyte differentiation or immune response, it is not reasonable to emphasize Clec5a too much over other genes, let alone highlighting it in the title of the manuscript.

5. There are several problems regarding the BioPlex analysis of cytokine levels. First, as this assay was performed using the media of cultured erythrocytes, the results may not reflect the in vivo cytokine secretion functions of the ABL-stimulated cells. Second, as most of the cytokines seemed to be undetectable in this assay, it is questionable whether the viability and functions of the cells are comparable with those in vivo or fresh isolated. Third, there is no inter-validation between the gene expression profiling and the BioPlex analysis results. These problems should be explained or at least discussed by providing more supporting information.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Xiao-Jian Sun

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0309455.r002
Author response to Decision Letter 0
Submission Version1
5 Aug 2024

Dear editor

Thank you for your notes and recommendations.

1. We revised the manuscript and made it in accordance with PlosOne requirements.

2. Roman Perik-Zavodskii edited the language level in this manuscript.

3. Indeed, there are some overlappings with our previous articles, but in this manuscript we added references in all places where we mentioned some from our previous articles

4. All needed data are in supplementary files (row data in particular)

Dear reviewer

First of all. Thank you for your revision and notes about our manuscript. We wanna respond to your notes.

1. We added some more information about erythropoiesis at acute blood loss conditions. Also, we wanna note that decreasing content of late erythron forms such as orthochomatic erythroblasts and reticulocytes connect with their exit into bloodstream as we suppose. Their exit can be consider like compensatory effect to replace loosed RBC after ABL.

2. Mentioned figures were replaced.

3. List of genes were replaced to the table.

4. We agree that Clec5a seems to be just one of the many differentially expressed genes. It need more pointed experiments and functional tests to proof role of this gene in erythron physiology. Now we biased the emphasis to chemokine CCL3, because its mRNA expression and protein production are detected in marrow erythroblasts. We suppose that erythroblasts are potent chemokine-producers and erythroblasts realize immunoregulatory effects via the chemokines.

5. About validation Nanostring (mRNA expression) and Bioplex data (protein production). We agree that in vivo and in vitro results may be different, because in vitro is some idealization model, which facilitate our work and so on. But in vitro model allow see clear affects for example in erythroid cells. We wanna note that we used fresh-isolated erythroid cells for flow cytometry and for Nanostrung analysis. Viability of isolated cells assayed by trypane blue test. Cell cultures were used to next procedures if their viability were 95% or more. At Nanostring analysis we applied more strict criterions to diminish threshold signals and extract these genes which are expressed exactly. And we see that production of protein have accordance with mRNA expression (IL1b, CCL2, CCL3). Also CCL3 expression level is equal Tal1 or CD36 expression level approximately (Tal1 and CD36 are signature genes of erythroid lineage). Although we detected other cytokines and chemokines genes expression we couldn’t check their protein production level by erythroblasts because that molecules (MIF, TGFb1, CXCL12, IL16) didn’t presented in Bioplex panel.

Attachment Submitted filename: Response to Reviewers.docx

10.1371/journal.pone.0309455.r003
Decision Letter 1
Stein Gary S. Academic Editor
© 2024 Gary S. Stein
2024
Gary S. Stein
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version1
12 Aug 2024

Acute blood loss in mice forces differentiation of both CD45-positive and CD45-negative erythroid cells and leads to a desreased CCL3 chemokine production by bone marrow erythroid cell

PONE-D-24-19541R1

Dear Dr. Sennikov,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gary S. Stein

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

10.1371/journal.pone.0309455.r004
Acceptance letter
Stein Gary S. Academic Editor
© 2024 Gary S. Stein
2024
Gary S. Stein
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
23 Aug 2024

PONE-D-24-19541R1

PLOS ONE

Dear Dr. Sennikov,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Gary S. Stein

Academic Editor

PLOS ONE
==== Refs
References

1 Sennikov SV , Injelevskaya TV , Krysov SV , Silkov AN , Kovinev IB , Dyachkova NJ , et al . Production of hemo-and immunoregulatory cytokines by erythroblast antigen+ and glycophorin A+ cells from human bone marrow. BMC Cell Biology. 2004 Dec;5 :1–6. doi: 10.1186/1471-2121-5-39 14711384
2 Perik-Zavodskaia O , Perik-Zavodskii R , Nazarov K , Volynets M , Alrhmoun S , Shevchenko J , et al . Murine Bone Marrow erythroid Cells Have Two Branches of Differentiation Defined by the Presence of CD45 and a Different Immune Transcriptome Than Fetal Liver erythroid Cells. International Journal of Molecular Sciences. 2023 Oct 30;24 (21 ):15752. doi: 10.3390/ijms242115752 37958735
3 Denisova VV , Kulagin AD , Lisukov IA , Kryuchkova IV , Sizikova SA , Sennikov SV , et al . Cytokine-producing activity of bone marrow erythrokaryocytes and its regulation under normal conditions. Bulletin of Experimental Biology and Medicine. 2007 Feb;143 :218–21. doi: 10.1007/s10517-007-0055-5 17970206
4 Nazarov K , Perik-Zavodskii R , Perik-Zavodskaia O , Alrhmoun S , Volynets M , Shevchenko J , et al . Phenotypic Alterations in erythroid Nucleated Cells of Spleen and Bone Marrow in Acute Hypoxia. Cells. 2023 Dec 10;12 (24 ):2810. doi: 10.3390/cells12242810 38132130
5 Kolbus A , Blázquez-Domingo M , Carotta S , Bakker W , Luedemann S , von Lindern M , et al . Cooperative signaling between cytokine receptors and the glucocorticoid receptor in the expansion of erythroid progenitors: molecular analysis by expression profiling. Blood. 2003 Nov 1;102 (9 ):3136–46. doi: 10.1182/blood-2003-03-0923 12869505
6 Socolovsky M. Molecular insights into stress erythropoiesis. Curr Opin Hematol. 2007;14 (3 ):215–224. doi: 10.1097/MOH.0b013e3280de2bf1 17414210
7 Valent P , Büsche G , Theurl I , et al . Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica. 2018;103 (10 ):1593–1603. doi: 10.3324/haematol.2018.192518 30076180
8 Niho Y , Asano Y . Fas/Fas ligand and hematopoietic progenitor cells. Curr Opin Hematol. 1998;5 (3 ):163–165. doi: 10.1097/00062752-199805000-00002 9664153
9 Srole DN , Ganz T . Erythroferrone structure, function, and physiology: Iron homeostasis and beyond. J Cell Physiol. 2021;236 (7 ):4888–4901. doi: 10.1002/jcp.30247 33372284
10 Kautz L , Jung G , Valore EV , Rivella S , Nemeth E , Ganz T . Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014 Jul;46 (7 ):678–84. Epub 2014 Jun 1. Erratum in: Nat Genet. 2020 Apr;52(4):463. doi: 10.1038/ng.2996 ; PMCID: PMC4104984.24880340
11 Melsen JE , van Ostaijen-Ten Dam MM , Lankester AC , Schilham MW , van den Akker EB . A comprehensive workflow for applying single-cell clustering and pseudotime analysis to flow cytometry data. The Journal of Immunology. 2020 Aug 1;205 (3 ):864–71. doi: 10.4049/jimmunol.1901530 32591399
12 Bedre Renesh . reneshbedre/bioinfokit: Bioinformatics data analysis and visualization toolkit. Zenodo; 2022. doi: 10.5281/zenodo.3964972
13 Fang Z , Liu X , Peltz G . GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics. 2023 Jan 1;39 (1 ):btac757. doi: 10.1093/bioinformatics/btac757 36426870
14 Shahbaz S , Xu L , Osman M , Sligl W , Shields J , Joyce M , et al . erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2. Stem cell reports. 2021 May 11;16 (5 ):1165–81. doi: 10.1016/j.stemcr.2021.04.001 33979601
15 Perik-Zavodskii R , Perik-Zavodskaia O , Shevchenko J , Denisova V , Alrhmoun S , Volynets M , et al . Immune Transcriptome Study of Human Nucleated erythroid Cells from Different Tissues by Single-Cell RNA-Sequencing. Cells. 2022 Nov 9;11 (22 ):3537. doi: 10.3390/cells11223537 36428967
16 Perik-Zavodskii R , Perik-Zavodskaya O , Shevchenko Y , Denisova V , Nazarov K , Obleuhova I , et al . Immune Transcriptome and Secretome Differ between Human CD71+ erythroid Cells from Adult Bone Marrow and Fetal Liver Parenchyma. Genes. 2022 Jul 26;13 (8 ):1333. doi: 10.3390/genes13081333 35893070
17 Grzywa TM , Nowis D , Golab J . The role of CD71+ erythroid cells in the regulation of the immune response. Pharmacology & therapeutics. 2021 Dec 1;228 :107927. doi: 10.1016/j.pharmthera.2021.107927 34171326
18 Sung PS , Hsieh SL . CLEC2 and CLEC5 A: pathogenic host factors in acute viral infections. Frontiers in immunology. 2019 Dec 6;10 :501049. doi: 10.3389/fimmu.2019.02867 31867016
19 Hemshekhar M , Piyadasa H , Mostafa D , Chow LN , Halayko AJ , Mookherjee N . Cathelicidin and calprotectin are disparately altered in murine models of inflammatory arthritis and airway inflammation. Frontiers in immunology. 2020 Aug 20;11 :557260. doi: 10.3389/fimmu.2020.01932 32973796
20 Thomas J , Liu F , Link DC . Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Current opinion in hematology. 2002 May 1;9 (3 ):183–9. doi: 10.1097/00062752-200205000-00002 11953662
21 An X , Schulz VP , Mohandas N , Gallagher PG . Human and murine erythropoiesis. Current opinion in hematology. 2015 May 1;22 (3 ):206–11. doi: 10.1097/MOH.0000000000000134 25719574
22 Liang R , Lin M , Menon V , Qiu J , Menon A , Breda L , et al . Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis. Blood Advances. 2023 Nov 28;7 (22 ):6873–85. doi: 10.1182/bloodadvances.2022007655 37672319
23 Becker-Herman S , Rozenberg M , Hillel-Karniel C , Gil-Yarom N , Kramer MP , Barak A , et al . CD74 is a regulator of hematopoietic stem cell maintenance. PLoS biology. 2021 Mar 4;19 (3 ):e3001121. doi: 10.1371/journal.pbio.3001121 33661886
24 Kapellos TS , Bonaguro L , Gemünd I , Reusch N , Saglam A , Hinkley ER , et al . Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Frontiers in immunology. 2019 Aug 30;10 :2035. doi: 10.3389/fimmu.2019.02035 31543877
25 Suryono Kido JI , Hayashi N, Kataoka M, Nagata T. Calprotectin expression in human monocytes: induction by porphyromonas gingivalis lipopolysaccharide, tumor necrosis factor‐α, and interleukin‐1β. Journal of periodontology. 2005 Mar;76 (3 ):437–42. doi: 10.1902/jop.2005.76.3.437
26 Puthenparampil M , Stropparo E , Zywicki S , Bovis F , Cazzola C , Federle L , et al . Wide cytokine analysis in cerebrospinal fluid at diagnosis identified CCL-3 as a possible prognostic factor for multiple sclerosis. Frontiers in Immunology. 2020 Mar 5;11 :174. doi: 10.3389/fimmu.2020.00174 32194540
27 Liu L , Yu Z , Cheng H , Mao X , Sui W , Deng S , et al . Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Scientific Reports. 2020 Nov 25;10 (1 ):20508. doi: 10.1038/s41598-020-77450-y 33239656
28 Perik-Zavodskii R , Perik-Zavodskaia O , Shevchenko J , Volynets M , Alrhmoun S , Nazarov K , et al . A subpopulation of human bone marrow erythroid cells displays a myeloid gene expression signature similar to that of classic monocytes. PloS one. 2024 Jul 22;19 (7 ):e0305816. doi: 10.1371/journal.pone.0305816 39038020
